Chapter 28: Drugs for Bipolar Disorder

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Usually when we talk about a medical diagnosis,

there is a certain expectation of precision.

Right, like it's a math problem or something.

Exactly.

I mean, you break your arm, the x -ray shows a jagged white line, and the provider just points at the film and says, you know, there it is.

That's the problem.

Broken or not broken, that kind of diagnostic clarity is, well, it's incredibly comforting.

Yeah, it really is.

But the moment you step into the world of clinical pharmacology and specifically psychiatric care, that x -ray machine is totally useless.

Completely useless.

We find ourselves navigating a diagnostic and therapeutic landscape that is quite honestly pretty murky.

And if you are an advanced practice nursing or physician assistant student,

those muddy waters can feel incredibly overwhelming, especially when you are suddenly the one responsible for prescribing.

Oh, absolutely.

The stakes are incredibly high and the drug mechanisms are really complex.

Which is exactly why we're here.

The goal of this deep dive is to clear the mud.

By the end of this session, you're going to understand exactly how the underlying pathophysiology of bipolar disorder drives your therapeutic goals.

And more importantly, how those goals dictate safe, rational drug selection and monitoring.

You know, you are not just going to memorize a list of medications today.

Right.

Rope memorization won't save you in clinical practice.

You're going to understand the physiological reasoning behind every single clinical decision you make.

To make sure we keep you laser focused on exactly what you need to know for your boards and your practice, we have a strict rule today.

Yes, absolutely no outside material.

We are sticking exclusively to the text of Chapter 28 from the third edition of Lean's Pharmacotherapeutics for Advanced Practice Nurses and Physician Assistants.

Just the requested chapter, nothing else.

We're going to explore how to navigate this muddy pharmacological landscape by starting with the physical brain itself.

Because before we can choose a drug, we kind of have to know what we're trying to fix.

Exactly.

So bipolar disorder, or BPD, affects about 2 .8 % of the adult population.

And the most vital concept to anchor yourself to, and honestly, to make sure your patients understand, is that this is a severe biologic illness.

It's not just a personality quirk or a character flaw.

No, not at all.

It is characterized by recurrent fluctuations in mood, and it's driven by physically altered brain physiology.

Right.

And, you know, we are assuming you already know the basic clinical presentation of a standard manic or major depressive episode.

Like, you know what euphoria, grandiosity, and sleight of ideas look like.

Just as you'd recognize the severe loss of pleasure and sleep disruption in major depression, what we really need to focus on right now are the specific patterns of this disorder.

Like distinguishing between bipolar I and bipolar II.

Yes.

So bipolar disorder means the patient experiences pure manic or mixed episodes,

and they usually experience depressive episodes as well.

Okay, so bipolar has the pure mania.

What about bipolar II?

Bipolar II disorder means the patient experiences hyper manic episodes, which are milder.

You know, they do not cause marked impairment or require hospitalization, along with depressive episodes.

So the key distinction is that a bipolar II patient never experiences a pure manic or mixed episode.

Exactly.

I want to pause on the term mixed episode for a second, because the clinical gravity of this specific presentation really cannot be overstated.

No, it can't.

It's incredibly dangerous.

A mixed episode means the patient is experiencing symptoms of mania and depression simultaneously,

Yes.

And the clinical danger there is just massive.

I mean, the patient might be highly agitated, completely restless and full of this manic energy, but simultaneously feeling entirely worthless and intensely depressed.

Which sounds like a terrifying combination.

It is.

When you pair high energy and impulsivity with deep depressive despair, the risk for suicide just skyrockets.

It is a true psychiatric emergency.

Wow.

So what is actually happening in the brain to cause these drastic fluctuations?

I mean, for a long time, the prevailing theory was simply a chemical imbalance, right?

Like a vague issue with neurotransmitter levels.

Right.

But the current text points to a much more structural problem.

The field has moved far beyond simple neurotransmitter imbalances.

So it's not just about serotonin or dopamine being too low or too high.

No, it's deeper than that.

Today, researchers believe the root cause is a disruption of neuronal growth and survival.

Neuroimaging actually shows that prolonged mood disorders are associated with tangible atrophy of specific brain regions.

Wait, actual atrophy?

Like the brain is shrinking?

Yes.

Specifically, the subgenual prefrontal cortex, which is a region heavily involved in regulating emotion.

That is wild.

So untreated BPD is almost like a muscle wasting away.

But specifically, the brain regions tied to emotion.

That is a great analogy.

It is atrophying.

The physical architecture responsible for emotional regulation is degrading over time.

Which completely reframes how we view our treatment strategy.

I mean, if we were dealing with physical brain atrophy, our drugs aren't just tweaking chemical levels to make someone feel a little better.

Exactly.

They must be actively protecting the brain from further structural damage.

That underlying pathophysiology directly dictates the mechanism of our treatments.

So mood -stabilizing drugs are doing more than just suppressing symptoms.

Much more.

They actually influence the signaling pathways that regulate neuronal growth.

They can prevent or even reverse this neuronal atrophy.

Okay, let's talk about how we choose those drugs then.

The chapter outlines three main classes.

Mood stabilizers,

antipsychotics, and antidepressants.

And the clinical guidelines for acute therapy are highly specific here.

For acute mania, the preferred drugs are lithium or valproate, often combined with a second generation atypical antipsychotic.

But if we are looking at an acute depressive episode,

the approach changes, doesn't it?

It does.

You might use a mood stabilizer alone or maybe an atypical antipsychotic.

But the golden rule in the text, and this is a foundational safety principle, is that you rarely, if ever, use an antidepressant alone in a patient with BPD.

Which feels incredibly counterintuitive.

I mean, if a patient is sitting in your clinic, severely depressed, barely able to function,

it almost seems cruel to withhold an antidepressant.

I know, it does seem backward at first glance.

Are we essentially saying that without a mood stabilizer acting as a physiological anchor, giving an antidepressant might slingshot the patient straight past a normal mood and up into a severe manic episode?

The slingshot concept perfectly illustrates the clinical fear here.

The long -held belief is that unopposed antidepressants can elevate moods so drastically that they induce hypomania or full -blown mania.

And we definitely want to avoid that.

Right.

Now, recent data suggests this risk might be slightly lower than previously feared, but current clinical guidelines remain strict.

You continue the traditional practice.

Meaning you only prescribe an antidepressant if a mood stabilizer is actively on board.

Exactly.

And even with a mood stabilizer on board, drug selection really matters.

Triceclic antidepressants or TCAs are specifically avoided.

Why TCAs in particular?

They appear to promote more incidence of mania than other classes.

So if you absolutely need an antidepressant, the experts prefer bupropion, venlafaxine, or SSRIs like fluoxetine or sertraline.

Okay, so we have our acute strategies.

But what about long -term preventative treatment?

The text mentions that adherence is a massive hurdle.

It is the largest hurdle.

Preventing recurrence requires lifelong medication.

But adherence is notoriously poor, particularly during or leading up to a manic episode.

Because euphoria feels good.

I mean, if a patient feels energetic, confident, and just on top of the world, they simply do not believe they are sick.

Why would they take a medication to turn off that feeling?

Exactly.

Which is why the initial stages of treatment often require short -term hospitalization, where medication administration can be directly observed.

And for outpatient care?

For long -term outpatient care, utilizing long -acting depot preparations, which are administered via injection every few weeks, can really help.

It bypasses the daily decision of whether or not to swallow a pill.

Collaboration with the patient's family is also essential to monitor for subtle signs of relapse.

Okay, since mood stabilizers are the foundation of this entire treatment architecture, let's look at the gold standard first.

Lithium.

The prototype.

Right.

It was first described for this use back in 1949,

and it remains a heavy hitter today.

And chemically, lithium is incredibly simple.

I mean, it is just an inorganic ion carrying a single positive charge.

It sits on the periodic table right alongside potassium and sodium.

But its impact on the brain is profound, right?

Right.

Very.

Animal studies show that therapeutic doses of lithium actually double the level of neurotrophic Bcl2 proteins.

It actively increases total gray matter in those exact regions that tend to atrophy in bipolar disorder.

So it is quite literally rebuilding the regulatory centers of the brain.

That's amazing.

But the pharmacokinetics, you know, how the body processes lithium, that is where things get highly clinical and potentially very dangerous.

Yes.

Lithium has a short half -life due to rapid renal excretion.

It is filtered and excreted by the kidneys.

But the critical physiological concept here is that the kidney processes lithium and sodium in the exact same way.

This is the single most important pharmacokinetic principle of lithium therapy.

You cannot safely prescribe this drug without understanding the sodium connection.

Right.

So the way I picture it, it's like the kidney is a bouncer at a crowded nightclub.

Okay.

I like where this is going.

And this bouncer is completely face blind to identical twins.

And those twins are sodium and lithium.

The bouncer just knows he needs a certain number of these positively charged guys inside the club to keep the internal environment balanced.

Right.

Maintaining homeospaces.

Exactly.

So if sodium leaves the club,

say the patient sweats heavily during a summer run or has severe diarrhea, the bouncer grabs lithium at the door to keep the numbers up.

He pulls lithium back in.

Yep.

The kidney retains the lithium to compensate for the lost sodium.

And suddenly we have a highly toxic lithium party in the bloodstream.

That analogy captures the exact mechanism of toxicity perfectly.

If a patient is sodium depleted for any reason, the kidney will reabsorb lithium in the proximal tubule.

And because lithium has an incredibly narrow therapeutic index,

that retention is bad news.

It rapidly leads to fatal toxicity.

So your patient education must heavily emphasize maintaining a normal consistent sodium intake and staying perfectly hydrated.

The clinical warnings about this narrow therapeutic window are severe.

Lithium toxicity is directly related to serum levels, meaning you must have facilities for prompt and accurate blood draws before you even initiate therapy.

Absolutely.

The levels must be kept strictly below 1 .5 mEq per liter.

What's the ideal range?

The ideal therapeutic range is between 0 .4 and 1.

Generally, keeping the patient between 0 .6 and 0 .8 is effective and safe.

And timing matters for those blood draws, right?

Very much so.

To monitor this accurately, blood should be drawn in the morning exactly 12 hours after the evening dose.

Okay.

So what do we need to watch for clinically?

The text separates adverse effects into two distinct categories.

Things that happen at therapeutic levels and things that happen at toxic levels.

Right.

So even when the drug is perfectly within that 0 .4 to 1 range, patients can experience side effects.

Things like excessive thirst, a fine hand tremor, GI upset, and massive polyuria.

Massive polyuria.

Like, how much?

Sometimes outputting over 3 liters of urine a day.

Wow.

And that polyuria is a perfect example of how understanding the underlying mechanism dictates your drug selection for side effect management.

Exactly.

Because lithium induces polyuria by antagonizing antidiuretic hormone at the collecting duct of the kidney.

Normally, to treat polyuria, a clinician might instinctively reach for a thiazide diuretic.

But think back to our bouncer analogy.

Thiazide diuretics deplete sodium.

And if you deplete sodium, the kidney retains lithium and you throw your patient straight into lithium toxicity.

So thiazides are out.

What's the rational clinical choice to manage lithium -induced polyuria then?

It's amylaride.

Amylaride is a potassium -sparing diuretic that reduces the entry of lithium into the renal epithelial cells without dangerously depleting sodium.

That makes perfect sense.

Other therapeutic level side effects to monitor include goiter and hypothyroidism, right?

Yes.

Which means you need baseline and annual T3, T4, and TSH levels.

And teratogenesis is a major concern too.

Definitely.

Lithium should be absolutely avoided in the first trimester of pregnancy due to cardiac malformations and used with extreme caution thereafter.

Okay, so that is all at the therapeutic level.

What happens if those serum levels creep up, like if we cross that 1 .5 threshold?

We enter toxic territory.

Between 1 .5 and 2, you start seeing coarse hand tremors, confusion, and EPAG changes.

And above 2, or 2 .5?

Above 2 .5, the situation becomes dire.

You are looking at generalized seizures, severe hypotension, coma, and death.

And the scary part is there is no specific antidote for lithium toxicity.

No antidote.

So what do you do?

If the level gets that high, the only option is hemodialysis to physically scrub the ion from the blood.

Which highlights why knowing how the kidney handles lithium also explains the severe drug interactions.

Diuretics are dangerous because they promote sodium loss.

Right.

And anticholinergic drugs like older antihistamines or TCA's are dangerous because they cause urinary hesitancy.

Oh, I see.

If a patient has lithium -induced polyuria and suddenly cannot empty their bladder due to an anticholinergic.

The resulting bladder distension is absolutely agonizing,

but the NSAID interaction is the one that really demands attention.

Non -steroidal anti -inflammatory drugs.

They can increase lithium levels by, what, an astonishing 60 percent.

Up to 60 percent, yes.

The mechanism here is that NSAID suppress prostaglandin synthesis in the kidney.

Prostaglandins help maintain renal blood flow.

So when you suppress them, you drastically increase the renal reabsorption of lithium.

And we are talking about incredibly common over -the -counter medications here, right?

Like ibuprofen and naproxen.

Exactly.

Patients might just take them for a headache without thinking twice.

But the text specifically calls out two exceptions.

Aspirin and Solendak.

Yes.

For reasons that are clinically unique, those two do not increase lithium levels.

So if your patient on lithium has a headache or minor pain,

aspirin or Solendak are your safe evidence -based choices.

Okay.

So because lithium requires such rigorous monitoring and carries that razor -thin therapeutic index, it seems like the field of pharmacology desperately needed effective, safer alternative.

They did.

And this brings us to the repurposing of anti -seizure medications.

Three specific drugs in this class have proven highly effective for stabilizing mood.

Divalproxodium, carbamazepine, and lamotrichin.

Let's start with Divalproxodium, or Valproit.

Valproit has actually replaced lithium as the first -line drug for many patients.

It works faster.

It has a higher therapeutic index, so it is inherently safer from an overdose perspective.

And it generally has a better side effect profile.

Although lithium still remains superior in two crucial areas, right?

Preventing relapses and reducing the risk of suicide.

That's true.

Lithium still holds the crown there.

But when you study these anti -seizure drugs, their defining features are often their black box warnings.

If I'm studying from my boards, it seems like the defining feature is just a list of horrors.

How does a clinician weigh these risks?

Well, a black box warning is not simply a stop sign.

It is a clinical roadmap.

It tells the clinician exactly what baseline data and ongoing monitoring parameters must be ordered to keep the patient safe.

Okay, so looking at Valproit, it carries black box warnings for severe hepatotoxicity and life -threatening pancreatitis.

It is also highly teratogenic, carrying severe fetal risks, including neural tube defects and decreased IQ.

So your clinical reasoning dictates your actions based on that roadmap.

Because of the hepatotoxicity risk, you must order baseline liver function tests, or LFTs, and monitor them periodically.

And for the pancreatitis?

You must educate the patient to immediately report severe abdominal pain, nausea, or anorexia, and be prepared to check serum amylase and lipase levels.

And obviously, the teratogenic risk means rigorous contraceptive counseling for patients of childbearing age.

Exactly.

Now, moving to carbamazepine, it requires a similar level of clinical vigilance.

It is highly effective for mania, with a target trough plasma level of 4 to 12 micrograms per milliliter.

But it has a fascinating and honestly dangerous pharmacokinetic quirk – autoinduction.

Yes.

Carbamazepine actually induces cytochrome P450 isoenzymes in the liver.

It stimulates the liver to build more of the specific metabolic machinery used to break drugs down.

Wait, does that mean a therapeutic dose prescribed on week one could become a completely subtherapeutic dose by week three, simply because the liver has become hyper -efficient at destroying it?

That is the exact clinical trap.

You have to monitor serum levels closely, and often increase the dosage during the first few weeks of therapy, just to maintain efficacy.

That's incredible.

And furthermore, this autoinduction accelerates the metabolism of other drugs metabolized by that same P450 pathway.

The most critical examples are oral contraceptives and warfarin.

Wow, so carbamazepine can render oral contraceptives entirely ineffective.

Yes.

Which is a massive issue when you are treating patients with potentially teratogenic psychiatric medications.

Carbamazepine also has black box warnings for serious dermatologic reactions, like Stevens -Johnson syndrome, as well as a plastic anemia and a granulocytosis.

So following our clinical roadmap rule,

complete blood counts, or CBCs, including platelets, are absolutely mandatory at baseline and periodically thereafter.

You are actively watching for that bone marrow suppression.

The third anti -seizure drug is lamontrogeny.

It is mostly indicated for long -term maintenance to prevent effective relapses.

But it shares that severe black box warning regarding serious dermatologic reactions, specifically toxic epidermal necrolysis and Stevens -Johnson syndrome.

So patient education is paramount here.

You must instruct the patient to report any sign of a rash immediately, as these conditions can be rapidly fatal.

Exactly.

Any rash needs immediate attention.

Sometimes, however, mood stabilizers just aren't enough to control acute manic symptoms right away, or a patient needs long -term maintenance from an entirely different angle.

Which leads us to our final drug class, antipsychotics.

And it is important to clarify here that in bipolar disorder, antipsychotics are used to help control symptoms during severe manic episodes, even if psychotic symptoms are entirely absent.

It's fascinating that a drug class named antipsychotic is being used to treat patients without psychosis.

It sounds like an off -label workaround simply to help reel in that severe hyperactivity.

It does sound like that, but it is a frontline strategy.

It reinforces the concept that the label on the box does not dictate the full physiological utility of the drug.

We are utilizing the drug's ability to modulate dopamine and serotonin pathways to achieve patient -centered mood stabilization.

The text emphasizes a strong preference for second -generation, or atypical, antipsychotics over the older, first -generation, conventional ones.

Right.

The clinical rationale here is that the atypicals carry a much lower risk of extra -pyramidal side effects, you know, the severe, sometimes irreversible movement disorders, and tardive dyskinesia.

The major approved atypical agents include drugs like olanzapine, ketchapine, risperidone, aripiprazole, and zeprasidone.

And they are highly effective against acute mania, usually used as adjunctive therapy alongside lithium or Velpro.

But the text also highlights some crucial distinctions for long -term maintenance.

While many of these atypicals are used to broke down an acute manic episode, currently only three are approved for long -term use to prevent the recurrence of mood episodes.

Yes, and those are aripiprazole, olanzapine, and zeprasidone.

There is also a very specific combination drug designed for depressive episodes called Symbiax.

Symbiax.

That's a single pill that combines olanzapine, an atypical antipsychotic, with fluoxetine, an SSRI antidepressant.

Exactly.

That makes perfect sense based on our earlier rule.

It provides the mood -stabilizing anchor of the olanzapine simultaneously with the antidepressant of the fluoxetine right there in one dose, preventing the slingshot endomania.

You've got it perfectly.

Of course, all antipsychotics come with their own severe risks.

The chapter highlights a critical black box warning for this entire class.

Let me guess another roadmap.

Indeed.

Older adult patients with dementia -related psychosis treated with antipsychotic drugs are at an increased risk for death.

It is a sobering reminder of the physiological power these medications wield.

It really is a lot of risk to manage.

Narrow therapeutic windows, bone marrow suppression,

hepatotoxicity, metabolic auto -induction.

It's heavy stuff.

It is.

But when you tie it all back to the physical brain, the reasoning becomes incredibly clear.

I want you to consider the incredible paradigm shift in BPD treatment we've just outlined today.

How so?

Well, for decades, the medical community viewed this purely as an emotional imbalance, trying to forcefully correct a chemical scale.

But discovering that drugs like lithium actually promote tangible brain growth, increasing gray matter, doubling neurotrophic proteins, and providing physical neuroprotection, that radically shifts how we view chronic psychiatric care.

We are just managing moods.

We are physically preserving the brain's architecture.

Exactly.

You are protecting the physical integrity of the brain itself from ongoing atrophy.

Which brings us right back to those muddy waters of clinical pharmacology.

The diagnostic x -ray might be useless here, but when you understand the underlying physiology, when you know that this subgenual prefrontal cortex is actively atrophying, and that your precise drug selection is literally rebuilding that tissue.

While your lab orders protect the liver, kidneys, and bone marrow.

That muddy landscape turns into a very clear map.

And that map tells you exactly what to prescribe, what to monitor, and how to keep your patients safe.

And that is everything you need to master the pharmacology of bipolar disorder.

Keep that image of the brain's physical architecture in mind the next time you are deciding between a thiazide and amylaride, or weighing a black box warning.

Thank you for joining us on this clinical journey.

Until next time, a warm thank you from the Last Minute Lecture Team.

This has been the Deep Dive.